TransPharm two-track approach focusses on the one hand on the compounds itself by identifying greener and more sustainable-by-design Active Pharmaceutical Ingredients (APIs) and on the other hand reducing the environmental impact and resilience of the manufacturing process by optimizing the synthesis route of new APIs in continuous flow and by proposing greener alternative solvents. The aim of the project is to (i) analyse and predict flow behaviour and environmental biodegradability of APIs and their synthesis pathways; (ii) identify greener and more sustainable alternatives to pharmaceutical products / APIs of concern; (iii) reduce the footprint and create important shortcuts in synthetic schemes of APIs; and (iv) assess the sustainability of pharmaceuticals over their entire life cycle. To reach the envisaged aims, the project will deliver four toolboxes (consisting of digital tools and guidelines) for the development of greener pharmaceutical products and APIs. These toolboxes will be used to (v) assess the potential to move towards the transition to greener, more agile pharmaceutical production. In addition, TransPharm will elaborate on the business case for sustainable pharmaceutical products or APIs and what is needed to bring them to the market. The project will also make sure that (vi) key project results and knowledge are properly transferred towards targeted stakeholders. TransPharm?s outcome contribute to a Europe, that is self-sufficient by reducing dependence on API production in third countries; making the EU healthcare industry more competitive, sustainable and reliable, ensuring timely supply of essential medicines from particularly complex or critical supply and distribution chains and positioning EU as a leader in innovative technologies.

ReSolute Project aims to pave the way for the production, at full industrial scale, of novel, non-toxic and high performing solvent from wood biomass. The Chemical sector is today facing a number of challenges driving demand for higher performing and safer chemicals derived from biomass. In the meantime, in the face of declining demand for paper, the pulp and paper industry is actively exploring opportunities to diversify into new areas or business including bio-based chemicals. In response to these needs, Circa has developed, at demonstration scale, a proprietary process to produce a novel bio-paper sector. From LGO ca be derived a wide range of chemicals including solvents, specialty polymers, flavours & fragrances, pharmaceutical and agrochemical actives. Circa’s first commercial product – a novel solvent trademarked as Cyrene – has already been trialled by more than 400 compagnies and researchers across the world and, for a growing number of applications, outperforms traditional dipolar aprotic solvents such as NMP, DMF and DMAc, which are under intense regulatory pressure due to their toxicity. Building on Circa group’s unique experience gained over the last 10 years via its 4 pilots and its operating demonstration plant, one of ReSolute’s key objectives will be to build and successfully operate a first-of-its kind Flagship Cyrene plant. The biorefinery will be built in France on the Carling Saint-Avold platform site owned by Total. The Flagship plant is expected to be mainly fed with saw dust and have a nameplate capacity of 1,000 metric tonnes per year. To reach this ambitious target, ReSolute will bring together 11 key actors along the entire value chain and will look to valorize the main by-product (biochar) in the energy and activated carbon markets.